Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single institution experience

In a retrospective study of 87 patients with mantle cell lymphoma treated with 3 different induction regimens, we show that a modification of the Nordic regimen in which a standard, rather than dose-intense, R-CHOP alternating with high dose cytarabine is a highly effective pre-autologous hematopoietic cell transplantation therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Publication date: Available online 6 December 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukasık, Elifcan Aladag, Salih Aksu, Ibrahim C. Haznedaroglu, Nilgun Sayınalp, Osman Ozcebe, Umit Yavuz Malkan, Hakan GokerAbstractBackground and AimThe refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplan...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplantation (alloHSCT). The aim of this study is to evaluate the efficacy and feasibility of alloHSCT in patients with refractory AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 29 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): S. Venugopal, J. MascarenhasAbstractChronic neutrophilic leukemia (CNL) is a BCR–ABL1 negative myeloproliferative (MPN) neoplasm with notably dismal survival. The current 2016 WHO classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable MDS/MPN overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoiet...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThis review provides estimates for response and survival to aid in decision making when considering ASCT for patients with PCNSL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
IntroductionChronic graft-versus-host disease (cGVHD) affects up to 50% of the long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT), and is the leading cause of mortality in patients who survive to two years post-transplant. Unlike acute GVHD (aGVHD), the primary pathology in cGVHD is fibrotic, affecting the skin, and lacrimal and salivary glands, and shares many features with the autoimmune conditions Sjogrens syndrome and systemic sclerosis. Certain gastrointestinal microbiota compositions have been associated with these autoimmune conditions, and we thus hypothesized that the configuration of ...
Source: Blood - Category: Hematology Authors: Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biomarkers and the Microbiome Source Type: research
Conclusion: Liver injury associated with the autologous hematopoietic stem cell transplant, represented mainly by DILI and SOS, had a high incidence (18.9%) among the subjects in the study and was associated with an elevated mortality rate. Drug induced liver injury has been underestimated and deserves further studies.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 731. Clinical Autologous Transplantation: Results: Poster I Source Type: research
The evasion of apoptosis, or programmed cell death, is a hallmark of cancer, which promotes tumor initiation and progression. The evasion is in part attributable to the over-expression of anti-apoptotic proteins in the Bcl-2 family. In addition, chemotherapy and radiation can upregulate the expression of the Bcl-2 family in cancer cells, which renders them more resistance to cancer therapy. The most common Bcl-2 family member over-expressed in many solid tumor cells and a fraction of leukemia and lymphoma cells is Bcl-XL and its expression is also highly correlated with resistance to cancer therapy independent of p53 statu...
Source: Blood - Category: Hematology Authors: Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Source Type: research
Conclusion: The rDNA transcription inhibitor CX-5461 synergises in vitro and in vivo with panobinostat, and CX-5461 retains efficacy in the setting of bortezomib-resistant myeloma.ReferencesDrygin et al., Cancer Research 2011Bywater et al., Cancer Cell 2012Quin et al, Oncotarget, 2016Devlin et al., Cancer Discovery 2016Hein et al., Blood 2017DisclosuresHarrison: Janssen-Cilag: Other: Scientific advisory board.
Source: Blood - Category: Hematology Authors: Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I Source Type: research
Chimeric antigen receptor T cells (CART) targeting CD19 have shown substantial activity against leukemia and lymphoma, which motivated developing CART cell therapy for Multiple myeloma (MM). B cell maturation antigen (BCMA) is the target molecule in MM. Several kinds of CART targeting BCMA have been created from 2016. Among these, the Bluebird Bio uses the humanized murine BCMA scFv to make CART, the Nanjing Legend company uses the single-domain antibody targeting BCMA to make CART.The single-domain antibody refers to the heavy chain antibody naturally present in camel species, which has no light chain. All VHh (Variable r...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research
Multiple Myeloma (MM) is a disease of malignant plasma cells for which if left untreated, patients face a 6 month median survival (Osgood, 1960). New agents and combinations continue to improve MM outcomes, extending the median survival to 5 years; however, patients will ultimately succumb to the disease after exhausting treatment options (Fonseca et al., 2017). A novel class of drugs, BH3 mimetics, specifically inhibit the gatekeepers of apoptosis known as pro-survival BCL2 family members BCL2, MCL1 and BCL-xL (Figure 1A). BCL-2 selective BH3 mimetic, venetoclax (ABT-199), has shown promise in a subset of MM patients; how...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Study | Transplants